Heterogeneous survival responses of human gastric cancer clones to αDifluoromethylornithine in vitro

S. C. Barranco, P. J. Ford, Courtney Townsend

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The effects of αDifluoromethylornithine (DFMO)2 on survival of human gastric cancer clones were studied in vitro. The responses were dose and time dependent. Treatments which lasted for less than 12 h were cytotoxic at only the highest doses used. The greatest effects on survival were observed only when cells were treated for 48 and 72 h. The effects on the clones produced by such prolonged treatment durations were heterogeneous, with survival values differing by as much as 460%. By contrast, the clonal survival responses to short DFMO treatments (12 h) were very uniform (dose differential of only 19%); however, this uniformity in response could be achieved only by using non-pharmacological doses of DFMO. The heterogeneity in survival responses in the clones might be slightly associated with their levels of intracellular spermidine. Clones with the smallest amounts of intracellular spermidine at the start of treatment were most sensitive to DFMO. However, this association may not hold up with further testing in other gastric cancer clones or when studied in other cancer lines in vitro.

Original languageEnglish (US)
Pages (from-to)337-345
Number of pages9
JournalInvestigational New Drugs
Volume4
Issue number4
DOIs
StatePublished - Dec 1986

Fingerprint

Eflornithine
Stomach Neoplasms
Clone Cells
Survival
Spermidine
In Vitro Techniques
Neoplasms

Keywords

  • cell killing
  • heterogeneity
  • polyamines

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Heterogeneous survival responses of human gastric cancer clones to αDifluoromethylornithine in vitro. / Barranco, S. C.; Ford, P. J.; Townsend, Courtney.

In: Investigational New Drugs, Vol. 4, No. 4, 12.1986, p. 337-345.

Research output: Contribution to journalArticle

@article{b7958b7ccf694e63ab7bbf336f48e931,
title = "Heterogeneous survival responses of human gastric cancer clones to αDifluoromethylornithine in vitro",
abstract = "The effects of αDifluoromethylornithine (DFMO)2 on survival of human gastric cancer clones were studied in vitro. The responses were dose and time dependent. Treatments which lasted for less than 12 h were cytotoxic at only the highest doses used. The greatest effects on survival were observed only when cells were treated for 48 and 72 h. The effects on the clones produced by such prolonged treatment durations were heterogeneous, with survival values differing by as much as 460{\%}. By contrast, the clonal survival responses to short DFMO treatments (12 h) were very uniform (dose differential of only 19{\%}); however, this uniformity in response could be achieved only by using non-pharmacological doses of DFMO. The heterogeneity in survival responses in the clones might be slightly associated with their levels of intracellular spermidine. Clones with the smallest amounts of intracellular spermidine at the start of treatment were most sensitive to DFMO. However, this association may not hold up with further testing in other gastric cancer clones or when studied in other cancer lines in vitro.",
keywords = "cell killing, heterogeneity, polyamines",
author = "Barranco, {S. C.} and Ford, {P. J.} and Courtney Townsend",
year = "1986",
month = "12",
doi = "10.1007/BF00173506",
language = "English (US)",
volume = "4",
pages = "337--345",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Heterogeneous survival responses of human gastric cancer clones to αDifluoromethylornithine in vitro

AU - Barranco, S. C.

AU - Ford, P. J.

AU - Townsend, Courtney

PY - 1986/12

Y1 - 1986/12

N2 - The effects of αDifluoromethylornithine (DFMO)2 on survival of human gastric cancer clones were studied in vitro. The responses were dose and time dependent. Treatments which lasted for less than 12 h were cytotoxic at only the highest doses used. The greatest effects on survival were observed only when cells were treated for 48 and 72 h. The effects on the clones produced by such prolonged treatment durations were heterogeneous, with survival values differing by as much as 460%. By contrast, the clonal survival responses to short DFMO treatments (12 h) were very uniform (dose differential of only 19%); however, this uniformity in response could be achieved only by using non-pharmacological doses of DFMO. The heterogeneity in survival responses in the clones might be slightly associated with their levels of intracellular spermidine. Clones with the smallest amounts of intracellular spermidine at the start of treatment were most sensitive to DFMO. However, this association may not hold up with further testing in other gastric cancer clones or when studied in other cancer lines in vitro.

AB - The effects of αDifluoromethylornithine (DFMO)2 on survival of human gastric cancer clones were studied in vitro. The responses were dose and time dependent. Treatments which lasted for less than 12 h were cytotoxic at only the highest doses used. The greatest effects on survival were observed only when cells were treated for 48 and 72 h. The effects on the clones produced by such prolonged treatment durations were heterogeneous, with survival values differing by as much as 460%. By contrast, the clonal survival responses to short DFMO treatments (12 h) were very uniform (dose differential of only 19%); however, this uniformity in response could be achieved only by using non-pharmacological doses of DFMO. The heterogeneity in survival responses in the clones might be slightly associated with their levels of intracellular spermidine. Clones with the smallest amounts of intracellular spermidine at the start of treatment were most sensitive to DFMO. However, this association may not hold up with further testing in other gastric cancer clones or when studied in other cancer lines in vitro.

KW - cell killing

KW - heterogeneity

KW - polyamines

UR - http://www.scopus.com/inward/record.url?scp=0022881479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022881479&partnerID=8YFLogxK

U2 - 10.1007/BF00173506

DO - 10.1007/BF00173506

M3 - Article

VL - 4

SP - 337

EP - 345

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -